Validation of the partin nomogram for prostate cancer in a national sample.

PURPOSE The Partin tables are a nomogram that is widely used to discriminate prostate cancer pathological stages, given common preoperative clinical characteristics. The nomogram is based on patients undergoing radical prostatectomy at The Johns Hopkins Medical Institutions. We validated the Partin tables in a large, population based sample. MATERIALS AND METHODS The National Cancer Institute Surveillance, Epidemiology and End Results database was used to identify patients treated from 2004 to 2005 who underwent radical prostatectomy. The 2007 Partin tables were used to estimate the prevalence of positive lymph nodes, seminal vesicle invasion, extraprostatic extension and organ confined disease in men with prostate cancer in the database using clinical stage, preoperative prostate specific antigen and Gleason score. The discriminative ability of the tables was explored by constructing ROC curves. RESULTS We identified 11,185 men who underwent radical prostatectomy for prostate cancer in 2004 to 2005. The Partin tables discriminated well between patient groups at risk for positive lymph nodes and seminal vesicle invasion (AUC 0.77 and 0.74, respectively). The discrimination of extraprostatic extension and organ confined disease was more limited (AUC 0.62 and 0.68, respectively). The AUC for positive lymph nodes was 0.78 in white men, 0.73 in black men and 0.83 in Asian/Pacific Islander men (p = 0.17). The AUC for positive lymph nodes in men 61 years old or younger was 0.80 vs 0.74 in men older than 61 years (p = 0.03). CONCLUSIONS The Partin tables showed excellent discrimination for seminal vesicle invasion and positive lymph nodes. Discrimination of extraprostatic extension and organ confined disease was more limited. The Partin tables performed best in young men.

[1]  Tumor thickness predicts a five-year survival equally as well as more complex prognostic model , 2000 .

[2]  E. Klein,et al.  Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer. , 2008, Urology.

[3]  R. Riffenburgh,et al.  Grading inaccuracies in diagnostic biopsies revealing prostatic adenocarcinoma: implications for definitive radiation therapy. , 1995, International journal of radiation oncology, biology, physics.

[4]  A. Haese*,et al.  Percent free prostate‐specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower , 2008, Cancer.

[5]  A. Partin,et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.

[6]  James M Henning,et al.  How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. , 2002, The Journal of urology.

[7]  A W Partin,et al.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.

[8]  Y. Ben-Shlomo,et al.  Investigating Black‐White differences in prostate cancer prognosis: A systematic review and meta‐analysis , 2008, International journal of cancer.

[9]  M. Terris,et al.  The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer. , 2008, Urology.

[10]  A W Partin,et al.  Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. , 2000, The Journal of urology.

[11]  L. Capps Unequal Treatment: Confronting Racial and Ethnic Disparities in Healthcare , 2003 .

[12]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[13]  A. D'Amico,et al.  Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Walsh,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2003, The Journal of urology.

[15]  Pierre I Karakiewicz,et al.  Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer. , 2004, The Journal of urology.

[16]  A. Haese*,et al.  Partin Tables cannot accurately predict the pathological stage at radical prostatectomy. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  A. D'Amico,et al.  PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. , 2008, Urology.

[18]  Haiqun Lin,et al.  Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. , 2005, The Journal of urology.

[19]  Umberto Capitanio,et al.  External validation of the updated Partin tables in a cohort of North American men. , 2008, The Journal of urology.

[20]  G. Brier VERIFICATION OF FORECASTS EXPRESSED IN TERMS OF PROBABILITY , 1950 .

[21]  A. Renshaw,et al.  Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma , 2003, Cancer.

[22]  Umberto Capitanio,et al.  External validation of the updated partin tables in a cohort of French and Italian men. , 2009, International journal of radiation oncology, biology, physics.

[23]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[24]  F. Montorsi,et al.  Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer , 2006, BJU international.

[25]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[26]  Alan W Partin,et al.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. , 2007, Urology.

[27]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[28]  J. Moul,et al.  Percent tumor involvement and risk of biochemical progression after radical prostatectomy. , 2008, The Journal of urology.